BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37185852)

  • 1. Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study.
    Lu T; Chen Z; Cao Y; Ao L; Li Z; Gu X; Ren X; Wang Y; Zhang G; Xiang D; Chen M; Cai D; Hu P; Zhang D; Peng M; Shi X; Ren H
    J Med Virol; 2023 Apr; 95(4):e28730. PubMed ID: 37185852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.
    Ao L; Lu T; Cao Y; Chen Z; Wang Y; Li Z; Ren X; Xu P; Peng M; Chen M; Zhang G; Xiang D; Cai D; Hu P; Shi X; Zhang D; Ren H
    Emerg Microbes Infect; 2022 Dec; 11(1):1126-1134. PubMed ID: 35369854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV.
    Lv Z; Lv S; Li Q; Xia Y; Feng Z; Zhang H; Yang H; Wu Z; Zou N; Mo Q; Gu Q; Ying S; Wang X; Qin D; Wan C
    Front Immunol; 2023; 14():1264160. PubMed ID: 38045691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
    Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
    Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tale of two conditions: when people living with HIV meet three doses of inactivated COVID-19 vaccines.
    Tan Y; Zou S; Ming F; Wu S; Guo W; Wu M; Tang W; Liang K
    Front Immunol; 2023; 14():1174379. PubMed ID: 37404815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.
    Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
    BMC Infect Dis; 2023 Jan; 23(1):34. PubMed ID: 36670363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV.
    Zhan H; Gao H; Liu Y; Zhang X; Li H; Li X; Wang L; Li C; Li B; Wang Y; Dai E; Li Y
    J Med Virol; 2023 Jan; 95(1):e28428. PubMed ID: 36571267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
    Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
    Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral responses after primary and booster SARS-CoV-2 inactivated vaccination in patients with chronic hepatitis B virus infection: A longitudinal observational study.
    Chen Z; Huang T; He T; Zha G; Zhu Q; Zhang G; Xiang D; Chen M; Li H; Ling N; Lan Y; Shi X; Zhang D; Xu P; Pan Q; Song R; Cao J; Zhang Y; Xiang H; Feng Y; Yang Z; Zhang B; Shen W; Cai D; Peng M; Hu P; Ren H
    J Med Virol; 2023 Apr; 95(4):e28695. PubMed ID: 36946505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
    Wolff M; Charpentier P; Canals A; Vial C; Hormazábal J; Cortés J; Silva M
    Vaccine; 2024 Jan; 42(3):671-676. PubMed ID: 38123398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
    Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV.
    Zou S; Guo W; Wu S; Ming F; Tan Y; Wu M; Tang W; Liang K
    Front Immunol; 2022; 13():988304. PubMed ID: 36325346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
    PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study.
    Guo Q; Yang L; Peng R; Gao T; Chu X; Jiang D; Ke D; Ren H
    Front Public Health; 2022; 10():1067342. PubMed ID: 36620297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.
    Cai S; Liao G; Yu T; Gao Q; Zou L; Zhang H; Xu X; Chen J; Lu A; Wu Y; Li B; Peng J
    J Med Virol; 2022 Sep; 94(9):4224-4233. PubMed ID: 35585023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
    Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
    Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.
    Liu Y; Lu J; Zhan H; Yuan W; Li X; Kang H; Li H; Chen Y; Cheng L; Sun X; Zheng H; Wang W; Dai E; Li Y
    Virol Sin; 2023 Oct; 38(5):723-734. PubMed ID: 37487943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No difference in anti-spike antibody and surrogate viral neutralization following SARS-CoV-2 booster vaccination in persons with HIV compared to controls (CO-HIV Study).
    Kling KD; Janulis P; Demonbreun AR; Sancilio A; Berzins B; Krueger K; Achenbach C; Price R; Sullivan M; Caputo M; Hockney S; Zembower T; McDade TW; Taiwo B
    Front Immunol; 2022; 13():1048776. PubMed ID: 36700200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral Immune Response to Inactivated COVID-19 Vaccination at the 3rd Month among People Living with HIV.
    Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
    Res Sq; 2022 Jun; ():. PubMed ID: 35794897
    [No Abstract]   [Full Text] [Related]  

  • 20. Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV.
    Marchitto L; Chatterjee D; Ding S; Gendron-Lepage G; Tauzin A; Boutin M; Benlarbi M; Medjahed H; Sylla M; Lanctôt H; Durand M; Finzi A; Tremblay C
    Viruses; 2023 Sep; 15(10):. PubMed ID: 37896781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.